BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30066853)

  • 21. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
    Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
    Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C7a, a biphosphinic cyclopalladated compound, efficiently controls the development of a patient-derived xenograft model of adult T cell leukemia/lymphoma.
    Guimaraes-Correa AB; Crawford LB; Figueiredo CR; Gimenes KP; Pinto LA; Grassi MFR; Feuer G; Travassos LR; Caires ACF; Rodrigues EG; Marriott SJ
    Viruses; 2011 Jul; 3(7):1041-1058. PubMed ID: 21994769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
    Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
    J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
    Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
    Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
    Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
    Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells.
    Tomita M; Kawakami H; Uchihara JN; Okudaira T; Masuda M; Takasu N; Matsuda T; Ohta T; Tanaka Y; Ohshiro K; Mori N
    Int J Cancer; 2006 Feb; 118(3):765-72. PubMed ID: 16106398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia.
    Ishikawa C; Arbiser JL; Mori N
    Biochim Biophys Acta; 2012 Jul; 1820(7):879-87. PubMed ID: 22465179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
    Zhang LL; Pan HX; Wang YX; Guo T; Liu L
    Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of PKC-δ in HTLV-1-infected T cells.
    Mori N; Ishikawa C; Senba M
    Int J Oncol; 2015 Apr; 46(4):1609-18. PubMed ID: 25625567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein phosphatase 2A as a potential target for treatment of adult T cell leukemia.
    Mori N; Ishikawa C; Uchihara JN; Yasumoto T
    Curr Cancer Drug Targets; 2013 Oct; 13(8):829-42. PubMed ID: 24015987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
    Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
    Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
    Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
    Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol.
    Ishikawa C; Tafuku S; Kadekaru T; Sawada S; Tomita M; Okudaira T; Nakazato T; Toda T; Uchihara JN; Taira N; Ohshiro K; Yasumoto T; Ohta T; Mori N
    Int J Cancer; 2008 Dec; 123(11):2702-12. PubMed ID: 18798263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells.
    Moles R; Bai XT; Chaib-Mezrag H; Nicot C
    J Hematol Oncol; 2016 Nov; 9(1):121. PubMed ID: 27829440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
    Yan S; Li Z; Thiele CJ
    Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.